Search the Newsreel

Biotron Limited (ASX:BIT) Share Price Remains Unchanged as Stock Trades Within Daily Range

Avecho Biotechnology Limited (ASX:AVE) Share Price Remains Unchanged as Stock Trades Within Daily Range

Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus

Krystal Biotech (KRYS) reported strong Q2 2026 earnings with net income of US$54.77 million and 24% net product revenue growth for VYJUVEK, leading to a significant year-to-date share price return. Despite a recent short-term decline, the company is trading below analyst price targets, and …

Riot Platforms, Inc. Common Stock (Derivatives) price today, RIOT to USD live price, marketcap and chart

This CoinMarketCap page provides live price data for Riot Platforms, Inc. Common Stock (Derivatives) (RIOT), showing its current price, 24-hour performance, and market statistics. The article includes a chart, price performance metrics like all-time high and low, and information on market capitalization and supply. …

576,266 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Wasatch Advisors LP

Wasatch Advisors LP has acquired 576,266 shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) worth approximately $12.4 million, bringing institutional ownership in the company to 99.17%. Despite a reported wider-than-expected quarterly loss, Adaptive Biotechnologies saw a 21.5% year-over-year revenue increase. The stock is trading near its …

Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 3,000 shares under plan

Adaptive Biotechnologies' Chief Commercial Officer, MRD, Susan Bobulsky, sold 3,000 shares of common stock at $25.00 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on December 16, 2025. Following the sale, Bobulsky directly holds 396,989 …

Marriott Vacations Worldwide Corp (VAC) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Riot Platforms (RIOT) cae un 5,5 % tras conocerse el acuerdo de 9.100 millones de dólares con Anthropic AI. ¿Ha cambiado el panorama alcista?

Riot Platforms Goes ‘Nuclear’ – RIOT Stock Hits 4-Year High After Terrestrial Energy Deal

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics reported its Q2 2026 financial results, highlighting a productive meeting with the FDA for tabelecleucel, which confirmed the opportunity to resubmit its BLA. The company announced significant cost reductions and expects its current cash and investments to fund operations into mid-2027. Net …

Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales

Adaptive Biotechnologies (ADPT) stock appears fairly valued based on its discounted cash flow model, which places its intrinsic value close to its current share price. However, the stock looks expensive when evaluated using market multiples, particularly its P/S ratio, which is significantly higher than …

Broker Revenue Forecasts For Lakefront Biotherapeutics NV (AMS:LKFT) Are Surging Higher

Analysts have significantly upgraded their revenue forecasts for Lakefront Biotherapeutics NV (AMS:LKFT) for the current year, leading to increased optimism about the company's prospects. Despite the positive forecast revision, the company's projected sales still represent a substantial reduction compared to previous performance and are …

Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock

Susan Bobulsky, an insider at Adaptive Biotechnologies (NASDAQ:ADPT), sold 3,000 shares of the company's stock for $75,000, reducing her total holdings by 0.75%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, institutional investors own a significant 99.17% of …

Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 3,000 shares of common stock totaling $75,000 at $25.00 per share on August 10, 2026. This transaction was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high …

Deutsche Bank Adjusts Marriott Vacations Worldwide PT to $134 From $119, Maintains Buy Rating

Deutsche Bank has increased its price target for Marriott Vacations Worldwide (VAC) to $134 from $119, while reaffirming a Buy rating on the stock. This adjustment comes after the company reported its Q2 2026 earnings, which showed increased adjusted earnings and revenue. Marriott Vacations …

Marriott Vacations Worldwide Co (VAC) Stock Forecasts

Argus has raised its target price for Marriott Vacations Worldwide Corp (VAC) to $92.00. The company operates in the United States leisure industry, with its current stock price at $119.33. This report is part of broader market coverage by Argus, also including updates for …

First Tracks Biotherapeutics (TRAX) Earnings Date and Reports 2026 $TRAX

Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Oncolytics Biotech (NASDAQ:ONCY) reported a quarterly loss of $0.08 per share, missing analysts' consensus estimate of a $0.05 loss by $0.03. Despite the earnings miss, the stock rose 0.5% to $0.82, and institutional investors have been increasing their holdings. Analysts currently rate the stock …

Compte rendu d’appel aux résultats : NANO Nuclear dépasse les prévisions de BPA au T3 2026

Samsara Inc. (IOT) Stock Falls Amid Market Uptick: What Investors Need to Know

Samsara Inc. (IOT) closed the most recent trading day at $39.34, moving -2.43% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.26%. Meanwhile, the Dow lost 0.04%, and the Nasdaq, a tech-heavy index, added 0.54%. …

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology (VIR) reported significant financial improvements in Q2 2026, with $1.01 billion in cash and investments and $238.9 million in revenue, driven by a collaboration with Astellas. The company highlighted strong progress in its hepatitis delta program, with promising clinical trial results for …

Atara Biotherapeutics Q2 Results: Sales beat estimates, EPS in line

Atara Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of $(0.32), which was in line with analyst estimates. While the company's sales of $630,000 beat the consensus estimate by 71.82%, this figure still represented a significant 96.42% year-over-year decline from $17.575 million, and EPS swung from …

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates

Atara Biotherapeutics Inc (ATRA) reported second-quarter earnings per share of $-0.3200, missing analyst estimates by $0.10. The company's revenue for the quarter was $630K, falling short of the consensus estimate of $2.55M. The stock has seen a decline of -3.71% over the last three …

Lakefront Biotherapeutics (LKFT) repurchases 103,970 shares in €2.41M buyback tranche

Lakefront Biotherapeutics (LKFT) announced the repurchase of 103,970 ordinary shares between August 3 and August 7, 2026, for a total of €2,409,901.40. The shares were bought at an average price of €23.18 each, as part of a program initiated on June 9, 2026. Following …

ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources

Oncolytics Biotech Inc. (ONCY) reported a widened net loss of $9.4 million in Q2 2026, attributed to rising R&D and G&A expenses due to clinical trial expansion and increased stock-based compensation. While current cash is sufficient for near-term milestones, the company will require additional …

Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings that matched analyst expectations for a loss of $0.32 per share, while revenue of $0.63 million surpassed estimates. Despite ongoing negative profitability metrics, the stock rose 3.2% after the announcement. Institutional investors hold a significant portion of the …

First Tracks Biotherapeutics 2Q 2026: Net loss $(33.4M), EPS $(0.95) — 10-Q Summary

First Tracks Biotherapeutics reported a net loss of $(33.4M) and diluted EPS of $(0.95) for Q2 2026, an improvement compared to the previous year. The company's cash and cash equivalents stood at $168M as of June 30, 2026, with management indicating a funding runway …

First Tracks Biotherapeutics (TRAX) details $83.9M loss and $168M cash after spin-off

Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary

Atara Biotherapeutics reported second-quarter 2026 results with revenue of $0.63 million, a significant drop from the previous year, and a consolidated net loss of $9 million for the six months ending June 30, 2026. The company experienced a sharp decline in commercial revenue due …

Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Expects Cash and Cost Cuts to Fund Operations Into Mid-2027

Atara Biotherapeutics announced its second-quarter 2026 financial results, highlighting productive discussions with the FDA regarding the resubmission of its tabelecleucel BLA. The company reported a net loss of $4.8 million for the quarter but expects its current cash, cash equivalents, and short-term investments, combined …

IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast

Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund

Vir Biotechnology, Inc. director Robert J. More reported internal share transfers totaling 16,000 shares of common stock, executed on August 11, 2026. These transactions involved transferring shares held for Alta Partners NextGen Fund I, L.P. (APNG 1) for no consideration in connection with the …

Legend Biotech Shares Fall After Oppenheimer Downgrade

Legend Biotech's shares experienced a decline following an Oppenheimer downgrade from Outperform to Perform, citing potential pressures from competition and a CEO transition. Despite this, RBC maintained an Outperform rating for Legend Biotech, adjusting its price target slightly, due to positive outlooks on Carvykti …

Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028

Vir Biotechnology's cash reserves exceeded $1 billion in Q2 2026, extending its operational runway into late 2028, primarily due to a strategic collaboration with Astellas. This deal, involving a $240 million upfront payment and a $75 million equity investment, focuses on VIR-5500 for prostate …

Riot Platforms, Inc. Stock 12‑Month Price Target Raised to $32.52, Implies 68% Upside

Riot Platforms, Inc.'s average stock price target has been increased from $31.28 to $32.52 by 20 analysts, with individual forecasts ranging from $25 to $45. This new target suggests a potential upside of approximately 68% from its August 10 closing price. The consensus rating …